Mayo Clinic, Pathology Asia, and LifeStrands Announce Strategic Genomic Testing…

Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) announced a strategic investment and collaboration focused on advanced diagnostics and precision medicine. This partnership leverages Mayo Clinic Laboratories' global clinical expertise alongside PAH's regional market knowledge in Southeast Asia, Australia, and New Zealand. Genomics is central to the collaboration, which will be delivered through LifeStrands Genomics. William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, was appointed Scientific Adviser to PAH.

The collaboration aims to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia, and New Zealand. These tests apply to identifying genetic conditions, disease risk assessment, diagnosis, and treatment planning. The partnership allows healthcare providers to integrate genomic insights into personalized patient care.